nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

04.10.2023 | Original Article

Comparison of parametric imaging and SUV imaging with [⁶⁸ Ga]Ga-PSMA-11 using dynamic total-body PET/CT in prostate cancer

verfasst von: Ruohua Chen, Yee Ling Ng, Xinlan Yang, Yinjie Zhu, Lianghua Li, Haitao Zhao, Yun Zhou, Gang Huang, Jianjun Liu

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Standardized uptake value (SUV) has been prevalently used to measure [⁶⁸ Ga]Ga-PSMA-11 activity in prostate cancer, but it is susceptible to multiple factors. Parametric imaging allows for absolute quantification of tracer uptake and provides a better diagnostic accuracy that is crucial for lesion detection. However, the clinical significance of total-body parametric imaging of [⁶⁸ Ga]Ga-PSMA-11 remains to be fully assessed. Therefore, the aim of our study is to delve into the diagnostic implications of total-body parametric imaging of [⁶⁸ Ga]Ga-PSMA-11 PET/CT for patients with prostate cancer.

Methods

Twenty prostate cancer patients were included and underwent a dynamic total-body [⁶⁸ Ga]Ga-PSMA-11 PET/CT scan. An irreversible two-tissue compartment model (2T3k) was fitted for each tissue time-to-activity curve, and the net influx rate (K_i) was obtained. The image quality and semi-quantitative analysis of lesion-to-background ratio (LBR), signal-to-noise ratio (SNR), and contrast-to-noise ratio (CNR) were compared between parametric images and SUV images.

Results

Kinetic modeling using 2T3k demonstrated favorable model fitting in both normal organs and lesions. All of the lesions detected on SUV images (55–60 min) could be detected on K_i images. The correlation between K_i, SUV_mean, and SUV_max in both normal organs and pathological lesions was found to be positive and statistically significant. Conversely, a moderate positive correlations were found between K_i and K₁ (R = 0.69, P < 0.001; R = 0.61, P < 0.001) and K_i and k₃ (R = 0.69, P < 0.001; R = 0.62, P < 0.001), in normal organs and pathological lesions, respectively. Visual assessment in K_i images showed less image noise and higher lesions conspicuity compared to SUV images. K_i image-derived LBR, SNR, and CBR of pathological lesions including primary tumors (PTs), lymph node metastases (LNMs) and bone metastases (BMs), exhibited remarkably higher folds (1.4–3.6 folds) compared to those derived from SUV of corresponding lesions.

Conclusions

Total-body parametric imaging of [⁶⁸ Ga]Ga-PSMA-11 enhanced lesion contrast and improved lesion detectability compared to SUV images. This may potentially serve as an imaging biomarker and theranostic tool for precise diagnosis and treatment evaluation in prostate cancer patients.

Nur mit Berechtigung zugänglich

Adams MC, Turkington TG, Wilson JM, Wong TZ. A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol. 2010;195:310–20. https://doi.org/10.2214/AJR.10.4923.CrossRefPubMed

Bertoldo A, Rizzo G, Veronese M. Deriving physiological information from PET images: from SUV to compartmental modelling. Clin Translat Imaging. 2014;2:239–51. https://doi.org/10.1007/s40336-014-0067-x.CrossRef

Dimitrakopoulou-Strauss A, Pan L, Sachpekidis C. Kinetic modeling and parametric imaging with dynamic PET for oncological applications: general considerations, current clinical applications, and future perspectives. Eur J Nucl Med Mol Imaging. 2021;48:21–39. https://doi.org/10.1007/s00259-020-04843-6.CrossRefPubMed

Wang G, Rahmim A, Gunn RN. PET Parametric Imaging: Past, Present, and Future. IEEE Transact Radiat Plasma Med Sci. 2020;4:663–75. https://doi.org/10.1109/TRPMS.2020.3025086.CrossRef

Rahmim A, Lodge MA, Karakatsanis NA, Panin VY, Zhou Y, McMillan A, et al. Dynamic whole-body PET imaging: principles, potentials and applications. Eur J Nucl Med Mol Imaging. 2019;46:501–18. https://doi.org/10.1007/s00259-018-4153-6.CrossRefPubMed

Zhang X, Cherry SR, Xie Z, Shi H, Badawi RD, Qi J. Subsecond total-body imaging using ultrasensitive positron emission tomography. Proc Natl Acad Sci U S A. 2020;117:2265–7. https://doi.org/10.1073/pnas.1917379117.CrossRefPubMedPubMedCentral

Zhang X, Xie Z, Berg E, Judenhofer MS, Liu W, Xu T, et al. Total-Body Dynamic Reconstruction and Parametric Imaging on the uEXPLORER. J Nucl Med. 2020;61:285–91. https://doi.org/10.2967/jnumed.119.230565.CrossRefPubMedPubMedCentral

Zhang YQ, Hu PC, Wu RZ, Gu YS, Chen SG, Yu HJ, et al. The image quality, lesion detectability, and acquisition time of (18)F-FDG total-body PET/CT in oncological patients. Eur J Nucl Med Mol Imaging. 2020;47:2507–15. https://doi.org/10.1007/s00259-020-04823-w.CrossRefPubMed

Wen J, Zhu Y, Li L, Liu J, Chen Y, Chen R. Determination of optimal 68 Ga-PSMA PET/CT imaging time in prostate cancers by total-body dynamic PET/CT. Eur J Nucl Med Mol Imaging. 2022;49:2086–95. https://doi.org/10.1007/s00259-021-05659-8.CrossRefPubMed

10.

Chen R, Wang Y, Zhu Y, Shi Y, Xu L, Huang G, et al. The Added Value of (18)F-FDG PET/CT Compared with (68)Ga-PSMA PET/CT in Patients with Castration-Resistant Prostate Cancer. J Nucl Med. 2022;63:69–75. https://doi.org/10.2967/jnumed.120.262250.CrossRefPubMedPubMedCentral

11.

Yu H, Gu Y, Fan W, Gao Y, Wang M, Zhu X, et al. Expert consensus on oncological [(18)F]FDG total-body PET/CT imaging (version 1). Eur Radiol. 2023;33:615–26. https://doi.org/10.1007/s00330-022-08960-8.CrossRefPubMed

12.

Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, et al. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. J Nucl Med. 2018;59:469–78. https://doi.org/10.2967/jnumed.117.198119.CrossRefPubMed

13.

Wang Y, Li E, Cherry SR, Wang G. Total-Body PET Kinetic Modeling and Potential Opportunities Using Deep Learning. PET Clin. 2021;16:613–25. https://doi.org/10.1016/j.cpet.2021.06.009.CrossRefPubMedPubMedCentral

14.

Ringheim A, Campos Neto GC, Anazodo U, Cui L, da Cunha ML, Vitor T, et al. Kinetic modeling of (68)Ga-PSMA-11 and validation of simplified methods for quantification in primary prostate cancer patients. EJNMMI Res. 2020;10:12. https://doi.org/10.1186/s13550-020-0594-6.CrossRefPubMedPubMedCentral

15.

Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3:1–7. https://doi.org/10.1038/jcbfm.1983.1.CrossRefPubMed

16.

Sachpekidis C, Kopka K, Eder M, Hadaschik BA, Freitag MT, Pan L, et al. 68Ga-PSMA-11 Dynamic PET/CT Imaging in Primary Prostate Cancer. Clin Nucl Med. 2016;41:e473–9. https://doi.org/10.1097/RLU.0000000000001349.CrossRefPubMed

17.

Sachpekidis C, Eder M, Kopka K, Mier W, Hadaschik BA, Haberkorn U, et al. (68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:1288–99. https://doi.org/10.1007/s00259-015-3302-4.CrossRefPubMed

18.

Huang X, Zhou Y, Bao S, Huang SC. Clustering-based linear least square fitting method for generation of parametric images in dynamic FDG PET studies. Int J Biomed Imaging. 2007;2007:65641. https://doi.org/10.1155/2007/65641.CrossRefPubMedPubMedCentral

19.

Blomqvist G. On the construction of functional maps in positron emission tomography. J Cereb Blood Flow Metab. 1984;4:629–32. https://doi.org/10.1038/jcbfm.1984.89.CrossRefPubMed

20.

Zhou Y, Flores S, Mansor S, Hornbeck RC, Tu Z, Perlmutter JS, et al. Spatially constrained kinetic modeling with dual reference tissues improves (18)F-flortaucipir PET in studies of Alzheimer disease. Eur J Nucl Med Mol Imaging. 2021;48:3172–86. https://doi.org/10.1007/s00259-020-05134-w.CrossRefPubMedPubMedCentral

21.

Gjedde A. High- and low-affinity transport of D-glucose from blood to brain. J Neurochem. 1981;36:1463–71. https://doi.org/10.1111/j.1471-4159.1981.tb00587.x.CrossRef

22.

Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations J Cereb Blood Flow Metab. 1985;5:584–90. https://doi.org/10.1038/jcbfm.1985.87.CrossRefPubMed

23.

Wong DF, Gjedde A, Wagner HN Jr. Quantification of neuroreceptors in the living human brain. I. Irreversible binding of ligands. J Cereb Blood Flow Metab. 1986;6:137–46. https://doi.org/10.1038/jcbfm.1986.27.CrossRefPubMed

24.

Landis JR, Koch GG. An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. Biometrics. 1977;33:363–74. https://doi.org/10.2307/2529786.CrossRefPubMed

25.

Strauss DS, Sachpekidis C, Kopka K, Pan L, Haberkorn U, Dimitrakopoulou-Strauss A. Pharmacokinetic studies of [(68) Ga]Ga-PSMA-11 in patients with biochemical recurrence of prostate cancer: detection, differences in temporal distribution and kinetic modelling by tissue type. Eur J Nucl Med Mol Imaging. 2021;48:4472–82. https://doi.org/10.1007/s00259-021-05420-1.CrossRefPubMedCentral

26.

Sari H, Mingels C, Alberts I, Hu J, Buesser D, Shah V, et al. First results on kinetic modelling and parametric imaging of dynamic (18)F-FDG datasets from a long axial FOV PET scanner in oncological patients. Eur J Nucl Med Mol Imaging. 2022;49:1997–2009. https://doi.org/10.1007/s00259-021-05623-6.CrossRef

27.

Sari H, Eriksson L, Mingels C, Alberts I, Casey ME, Afshar-Oromieh A, et al. Feasibility of using abbreviated scan protocols with population-based input functions for accurate kinetic modeling of [(18)F]-FDG datasets from a long axial FOV PET scanner. Eur J Nucl Med Mol Imaging. 2023;50:257–65. https://doi.org/10.1007/s00259-022-05983-7.CrossRef

28.

Dias AH, Jochumsen MR, Zacho HD, Munk OL, Gormsen LC. Multiparametric dynamic whole-body PSMA PET/CT using [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007. EJNMMI Res. 2023;13:31. https://doi.org/10.1186/s13550-023-00981-8.CrossRefPubMedPubMedCentral

29.

Lu M, Lindenberg L, Mena E, Turkbey B, Seidel J, Ton A, et al. A Pilot Study of Dynamic (18)F-DCFPyL PET/CT Imaging of Prostate Adenocarcinoma in High-Risk Primary Prostate Cancer Patients. Mol Imaging Biol. 2022;24:444–52. https://doi.org/10.1007/s11307-021-01670-5.CrossRef

30.

Prasad V, Steffen IG, Diederichs G, Makowski MR, Wust P, Brenner W. Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions. Mol Imaging Biol. 2016;18:428–36. https://doi.org/10.1007/s11307-016-0945-x.CrossRefPubMed

31.

Hofman MS, Hicks RJ, Maurer T, Eiber M. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. Radiographics. 2018;38:200–17. https://doi.org/10.1148/rg.2018170108.CrossRefPubMed

32.

Rosar F, Wenner F, Khreish F, Dewes S, Wagenpfeil G, Hoffmann MA, et al. Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy. Eur J Nucl Med Mol Imaging. 2022;49:1584–94. https://doi.org/10.1007/s00259-021-05594-8.CrossRefPubMed

33.

Seifert R, Kessel K, Schlack K, Weber M, Herrmann K, Spanke M, et al. PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [(177)Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis. Eur J Nucl Med Mol Imaging. 2021;48:1200–10. https://doi.org/10.1007/s00259-020-05040-1.CrossRefPubMed

34.

Unterrainer LM, Beyer L, Zacherl MJ, Gildehaus FJ, Todica A, Kunte SC, et al. Total Tumor Volume on (18)F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with (225)Ac-PSMA-I&T. Biomedicines. 2022;10:946. https://doi.org/10.3390/biomedicines10050946.CrossRefPubMedPubMedCentral

35.

Cunningham VJ, Jones T. Spectral analysis of dynamic PET studies. J Cereb Blood Flow Metab. 1993;13:15–23. https://doi.org/10.1038/jcbfm.1993.5.CrossRefPubMed

Titel: Comparison of parametric imaging and SUV imaging with [68 Ga]Ga-PSMA-11 using dynamic total-body PET/CT in prostate cancer
verfasst von: Ruohua Chen
Yee Ling Ng
Xinlan Yang
Yinjie Zhu
Lianghua Li
Haitao Zhao
Yun Zhou
Gang Huang
Jianjun Liu
Publikationsdatum: 04.10.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 2/2024
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-023-06456-1

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Comparison of parametric imaging and SUV imaging with [⁶⁸ Ga]Ga-PSMA-11 using dynamic total-body PET/CT in prostate cancer

Abstract

Purpose

Methods

Results

Conclusions

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2024

PET/CT-based deep learning grading signature to optimize surgical decisions for clinical stage I invasive lung adenocarcinoma and biologic basis under its prediction: a multicenter study

Letter to the editor concerning “Reproducibility of [18F]FDG PET/CT liver SUV as reference or normalisation factor”

Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage Hodgkin’s lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgkin Study Group

Long-axial field-of-view PET/CT for the assessment of inflammation in calcified coronary artery plaques with [68 Ga]Ga-DOTA-TOC

In vivo cerebral metabolic and dopaminergic characteristics in multiple system atrophy with orthostatic hypotension

Proliferation and apoptosis after whole-body irradiation: longitudinal PET study in a mouse model